05:23 PM EDT, 05/21/2024 (MT Newswires) -- Rezolute ( RZLT ) reported positive topline results from a phase 2 clinical study of RZ402 in diabetic macular edema patients who are naive to or have received limited anti-vascular growth factor injections.

The study met the primary endpoints for good safety profile and reduction of central-subfield thickness, the company said Tuesday in a statement.

Rezolute ( RZLT ) said 94 participants in the US multicenter, placebo-controlled study received RZ402 as a monotherapy over a 12-week treatment period.

Shares of the company soared 50% in recent after-hours activity.

Price: 4.5000, Change: +1.50, Percent Change: +50.00